Michael B. Jarstfer
University of Utah
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael B. Jarstfer.
Journal of Biological Chemistry | 2006
Brian R. Keppler; Allen T. Grady; Michael B. Jarstfer
Telomerase is a ribonucleoprotein complex that synthesizes the G-rich DNA found at the 3′-ends of linear chromosomes. Human telomerase consists minimally of a catalytic protein (hTERT) and a template-containing RNA (hTR), although other proteins are involved in regulating telomerase activity in vivo. Several chaperone proteins, including hsp90 and p23, have demonstrable roles in establishing telomerase activity both in vitro and in vivo, and previous reports indicate that hsp90 and p23 are required for the reconstitution of telomerase activity from recombinant hTERT and hTR. Here we report that hTERT and hTR associate in the absence of a functional hsp90-p23 heterocomplex. We also report that hsp90 inhibitors geldanamycin and novobiocin inhibit recombinant telomerase even after telomerase is assembled. Inhibition by geldanamycin could be overcome by allowing telomerase to first bind its primer, suggesting a role for hsp90 in loading telomerase onto the telomere. Inhibition by novobiocin could not similarly be overcome but instead resulted in destabilization of the hTERT polypeptide. We propose that the hsp90-p23 complex fine tunes and stabilizes a functional telomerase structure, allowing primer loading and extension.
Journal of Medicinal Chemistry | 2014
Vijay G. Sekaran; Joana Soares; Michael B. Jarstfer
The observation that the enzyme telomerase is up-regulated in 80-90% of cancer cells isolated from primary human tumors but is absent in neighboring cells of healthy tissue has resulted in significant efforts to validate telomerase as an anticancer drug target and to develop effective approaches toward its inhibition. In addition to inhibitors that target the enzymatic function of telomerase, efforts toward immunotherapy using peptides derived from its catalytic subunit hTERT and hTERT-promoter driven gene therapy have made significant advances. The increased level of telomerase in cancer cells also provides a potential platform for cancer diagnostics. Telomerase inhibition leads to disruption of a cells ability to maintain the very ends of the chromosomes, which are called telomeres. Thus, the telomere itself has also attracted attention as an anticancer drug target. In this Perspective, interdisciplinary efforts to realize the therapeutic potential of targeting telomere maintenance with a focus on telomerase are discussed.
Tetrahedron Letters | 1995
Charles E. Chase; Michael B. Jarstfer; Atta M. Arif; F. G. West
Abstract Pyran-2-ones 2a–e bearing pendant alcohols underwent conversion to dihydropyrans 7 via irradiation in MeOH followed by stirring in the presence of catalytic HCl. This process requires the intervention of a prior skeletal rearrangement of the starting pyran-2-ones to place the hydroxyalkyl substituent at C-4, along with temporary incorporation of MeOH. Homologous substrates 2f–g underwent intramolecular 1,6-addition exclusively to furnish spirolactones 9 in good yield.
Biochemistry | 2011
Joana Soares; Margaret M. Lowe; Michael B. Jarstfer
Telomerase is a ribonucleoprotein complex that is essential for persistent cellular proliferation. The catalytic subunit of human telomerase, hTERT, functions as a reverse transcriptase and promotes vitality by maintaining telomeric DNA length. hTERT is tightly regulated with complex but poorly understood positive and negative regulation at several levels including transcription, protein-protein interactions, and post-translation modifications. Because evidence implicates hTERT as an apoptosis inhibitor and because telomerase activity tends to decrease during apoptosis, we hypothesized that hTERT is a caspase substrate leading to down regulation during apoptosis. Caspases are proteases that initiate and execute apoptosis by cleaving target proteins. Indeed, we found that caspases-6 and -7 cleave hTERT during apoptosis in cultured cells. Caspase-6 cleaves at residues D129 and D637, and caspase-7 cleaves at E286 and D628. Three of the caspase cleavage sites are unique motifs. All four caspase motifs appear conserved in TERTs from Old World monkeys and apes, and the caspase-6 sites appear conserved in all primates. The caspase site that cleaves at D129 appears conserved in amniotes. hTERT fragments generated by cleavage were remarkably persistent, lasting hours after caspase activation. These results reveal a new biologically relevant mechanism for telomerase down regulation through caspase-mediated cleavage of hTERT and expand the list of known caspase motifs.
Biochemistry | 1994
Jose A. Mendoza; Michael B. Jarstfer; David P. Goldenberg
Biochemistry | 2004
Brian R. Keppler; Michael B. Jarstfer
Journal of Organic Chemistry | 1995
Hans-Ulrich Humpf; Nina Berova; Koji Nakanishi; Michael B. Jarstfer; C. Dale Poulter
Biochemistry | 2002
Michael B. Jarstfer; Thomas R. Cech
Biochemistry | 2005
Jason D. Legassie; Michael B. Jarstfer
Biochemistry | 2006
Nicole Fouché; Ian K. Moon; Brian R. Keppler; Jack D. Griffith; Michael B. Jarstfer